Inhaled Corticosteroid Exposure in Hospitalized Infants with Bronchopulmonary Dysplasia.
Journal
American journal of perinatology
ISSN: 1098-8785
Titre abrégé: Am J Perinatol
Pays: United States
ID NLM: 8405212
Informations de publication
Date de publication:
07 Jun 2022
07 Jun 2022
Historique:
pubmed:
7
5
2022
medline:
7
5
2022
entrez:
6
5
2022
Statut:
aheadofprint
Résumé
The objective of this paper was to determine inhaled corticosteroid (IC) use in infants with bronchopulmonary dysplasia (BPD), define the interhospital variation of IC administration to infants with BPD, and compare clinical, demographic, and hospital factors associated with IC use. Using the Pediatric Health Information System database, a retrospective multicenter cohort of 4,551 infants born at <32 weeks of gestation with developing BPD was studied. The clinical, demographic, and hospital characteristics of infants exposed and not exposed to ICs were compared. IC use varied markedly between hospitals, ranging from 0 to 66% of infants with BPD exposed to ICs. Increased annual BPD census was not associated with IC use. In total, 25% (1,144 out of 4,551) of patients with BPD and 43% (536 out of 1,244) of those with severe BPD received ICs. Increased IC exposure was associated with lower birth weight and gestational age, days on respiratory support, need for positive pressure ventilation at 36-week postmenstrual age, need for tracheostomy, and increased use of systemic steroids, bronchodilators, and diuretics. IC exposure is common in infants with BPD, with substantial interhospital variability. IC use was associated with more severe disease. Hospital experience did not account for the wide variability in IC use by the hospital. Further research into the effects of ICs use is urgently needed to help guide their use in this vulnerable population. · The risks and benefits of IC use in infants with BPD are incompletely understood.. · IC use is common in infants with BPD (25%) and severe BPD (43%) varies widely by hospital (0-66% of patients with BPD received an IC).. · Hospital experience did not account for the wide interhospital variation in IC use..
Identifiants
pubmed: 35523409
doi: 10.1055/a-1845-2669
pmc: PMC9637235
mid: NIHMS1807976
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIH HHS
ID : UG1 OD024953
Pays : United States
Organisme : UG10D024953
ID : National Institutes of Health
Informations de copyright
Thieme. All rights reserved.
Déclaration de conflit d'intérêts
None declared.
Références
Pediatrics. 2016 Dec;138(6):
pubmed: 27940717
Pediatr Pulmonol. 2020 Feb;55(2):360-368
pubmed: 31794157
Pediatrics. 2008 Jul;122(1):e53-61
pubmed: 18595975
Semin Fetal Neonatal Med. 2017 Oct;22(5):296-301
pubmed: 28768578
J Pediatr. 2019 May;208:148-155.e3
pubmed: 30857774
J Perinatol. 2021 Jan;41(1):53-61
pubmed: 32759956
J Pediatr. 1999 Jul;135(1):65-70
pubmed: 10393606
J Clin Endocrinol Metab. 1998 Jul;83(7):2390-3
pubmed: 9661616
Pediatr Pulmonol. 2017 Jul;52(7):968-975
pubmed: 28165675
Birth Defects Res A Clin Mol Teratol. 2014 Mar;100(3):145-57
pubmed: 24639412
N Engl J Med. 2015 Oct 15;373(16):1497-506
pubmed: 26465983
Am J Perinatol. 2015 Aug;32(10):960-7
pubmed: 25738785
Pediatrics. 2006 Jun;117(6):1979-87
pubmed: 16740839
N Engl J Med. 2018 Jan 11;378(2):148-157
pubmed: 29320647
PLoS One. 2014 Sep 05;9(9):e106838
pubmed: 25192252
J Perinatol. 2021 Aug;41(8):1783-1796
pubmed: 34012057
J Pediatr. 2018 Jun;197:300-308
pubmed: 29551318
Am J Respir Crit Care Med. 2016 Jan 1;193(1):86-95
pubmed: 26351971
Cochrane Database Syst Rev. 2017 Oct 17;10:CD002058
pubmed: 29041034
N Engl J Med. 2012 Sep 6;367(10):904-12
pubmed: 22938716
Respir Care. 2018 Jun;63(6):655-670
pubmed: 29794202
Am J Perinatol. 2014 Oct;31(9):811-21
pubmed: 24347262
N Engl J Med. 2001 Jan 11;344(2):95-101
pubmed: 11150359